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ABSTRACT 
There has been a recent increase in the proportion of adolescents living with HIV being enrolled 
on anti-retroviral therapy (ART) in Botswana, with more than 90% accessing this life saving 
therapy. A significant proportion become lost-to-follow-up (LTFU) from the ART care, 
reversing the initial gains attained. The factors associated with lost-to-follow-up in this 
vulnerable HIV positive adolescent population in Botswana are generally unknown, as most 
studies on this subject are on the adult population.  
This study investigated the rate and factors associated with lost-to-follow up amongst middle and 
late adolescents (15-19 years) on ART at Botswana-Baylor clinic in Gaborone, Botswana. The 
center provides comprehensive HIV prevention, treatment and psychological services to children 
and adolescents living with HIV. The research intended to assist HIV program managers to 
retain adolescents in care, which is vital in reducing morbidity, mortality and also new HIV 
infections amongst this population. The research design was an observational comparison 
between those LTFU on ART and those retained on ART. Simple random sampling was used 
and the study had 133 of those LTFU and 133 of those not LTFU. Data on the risk factors were 
retrospectively extracted from patient records stored in a data-base at the clinic. The data were 
analyzed using Epi-info 7 statistical software to determine if there were any statistically 
significant factors associated with lost-to-follow-up amongst adolescents on ART. The study 
involved a vulnerable population who are HIV positive and a proportion who were less than 18 
years. However minimal harm was expected as this was a record review and data was 
anonymized prior to analysis. Ethical clearance was given by the Botswana Baylor Clinic Ethics 
Committee and the University of Western Cape Biomedical Ethics Research Committee. 
The LTFU rate in the clinic amongst adolescents (15-19 years) was 4.6%. Using bivariate 
analysis there were significant associations between LTFU and the following variables:  CD4 
count (prior to LTFU), detectable viral load, past history of Tuberculosis, PI-based ART regimen 
and suboptimal adherence. However after multivariate analysis, only detectable viral load and 
suboptimal adherence were independent predictors of lost-to-follow-up.  Middle and older 
adolescent patients lost-to-follow-up were 5 times more likely to have a detectable viral load and 
4 times more likely to have suboptimal adherence than those not lost-to-follow-up. The findings 
in our study will assist clinicians at the Baylor-Botswana clinic identify adolescent patients 
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needing extra support to be retained in care and improve clinical outcomes. More studies of this 
type are needed in solely public sector clinics in Botswana and regionally, as there is a sizeable 
population of people living with HIV in middle and late adolescents in which lost-to-follow up 
appears to be greatest.  
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                                           CHAPTER 1:  INTRODUCTION 
1.1 Background 
East and Southern Africa have the largest burden of the HIV epidemic compared to other regions 
in the world. According to UNAIDS, of the 36 million people living with HIV globally, 19 
million reside in Eastern and Southern Africa (UNAIDS, 2016). Approximately 5% of people 
living with HIV (PLHIV) are adolescents (10-19 years)
1
 and of the estimated 670 000 new 
infections amongst young adults (15-24 years) globally, approximately 37% were in the 15-19 
years age category (UNICEF, 2016). Of the estimated 1,8 million adolescents (10-19 years) 
living with HIV globally, 1,1 million are located in East and Southern Africa, 52% of global new 
infections amongst adolescents (10-19 years) and 60% of adolescent HIV-related global deaths 
occur in this same region (AIDS Info, 2016).  In this region adolescent females aged 15-19 years 
are reported to be four times at greater risk of becoming HIV infected compared to their male 
counterparts (Bekker & Hosele, 2015). 
Overall antiretroviral therapy (ART) coverage
2
 of PLHIV is estimated to be 53% in Eastern and 
Southern Africa (AIDS Info, 2016). Due to increased availability of ART, a significant 
proportion of children born with HIV are now reaching adolescence due to being on ART (Judd, 
Doerholt & Tookey, 2007). ART coverage rates amongst the adolescent population are 
frequently lacking, as data from most countries is not disaggregated by age category (Idele, 
Gillepsie & Porth, 2014). However ART coverage is thought to be generally lower compared to 
other age groups (Elizabeth Glazer Foundation, 2016). This may result in higher rates of HIV-
related morbidity and mortality in this age group. According to UNAIDS between 2005 and 
2012, HIV-related mortality amongst the adolescent population living with HIV had increased by 
about 50% although it had significantly fallen by about 30% amongst other age categories 
(Bekker & Hosele, 2015). 
 
                                                          
1
 Adolescents are defined as young people between the ages of 10-19 years (WHO, 2017)) 
2
  ART Coverage is defined as percentage of people living with HIV currently receiving ART among the estimated 
number of adults and children living with HIV (WHO, 2015). 
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Botswana has one of the highest burdens of the HIV epidemic. The HIV prevalence amongst 
adults 15-49 years in Botswana is estimated to be 25% and 16 000 children are living with HIV 
in a country with a population of about 2 million (UNAIDS, 2015).  Despite low pediatric and 
adolescent coverage globally, Botswana has a relatively very high ART coverage rate of about 
96% amongst adolescents (15-19 years) (UNICEF, 2014). 
Adolescents’ widespread access to ART in Botswana has improved their health status and 
clinical outcomes. Botswana, amongst sub-Saharan African countries such as Namibia, Zambia 
and Zimbabwe has seen a 50% decline of AIDS related deaths since 2005 (UNDP, 2013). 
Despite this significant decline in HIV/AIDS associated mortality, lifelong ART has created 
additional challenges, including retaining patients in HIV care. Whilst there is an estimated 12% 
attrition from ART in all age categories in Botswana, age-related data are lacking (Farahani, 
Vable & Lebelonyane, 2013). Medical measures of the success of an ART program can be 
measured by attributes such as virological suppression and survival of patients on ART, however 
the program cannot be deemed to be successful if there are significant rates of lost-to-follow-up 
(LTFU) in ART care.  While there is high ART coverage through initiation on treatment 
(UNICEF, 2014) a great challenge is to retain adolescents on life-long ART treatment. Complex 
psychosocial and environmental conditions affecting adolescents may affect ART adherence and 
retention in care (Naidoo, Munsami & Archary, 2015). The majority of studies conducted in 
Botswana on LTFU, using data from the national ART program do not make a distinction 
between adults and adolescents. It is therefore important to conduct a study to elucidate both the 
rates and factors affecting lost-to-follow-up specifically amongst adolescents living with HIV in 
Botswana. 
This study was conducted to provide information on rates of middle and late adolescent LTFU 
on ART and to examine the factors associated with adolescent LTFU at a children and 
adolescent HIV clinic in Gaborone, Botswana. This is intended to contribute to strategies to 
improve adolescent retention on antiretroviral (ARV) treatment and in care in this setting.  
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1.2 Research problem 
Botswana is one of the few African countries' to have achieved universal access to antiretroviral 
treatment with over 90% of adolescents living with HIV requiring treatment being on treatment 
(UNICEF, 2014).  Overall lost-to-follow-up (LTFU) in the Botswana national ART program is 
estimated to be approximately 17% at 2 years of follow up for all age groups (Farahani, Vable & 
Lebelonyane, 2013). These rates are expected to be higher in the adolescent age group given the 
social, behavioral and psychological challenges faced by teenagers in general and those living 
with HIV in particular.  Information is lacking on the frequency of LTFU on ART amongst 
adolescent patients and its influencing factors in Botswana. This threatens to diminish the 
success of the antiretroviral program in Botswana. There is a need to address the gap in 
knowledge on the rates of adolescent LTFU on ART and to understand the factors associated 
with this. 
1.3 Research Question 
What proportions of adolescents are LFTU and which factors are associated with LTFU amongst 
adolescent patients on antiretroviral therapy in an urban setting in Botswana? 
1.4 Purpose of study 
The purpose of this study is to advance our knowledge and understanding of the extent of LTFU 
and factors associated with LTFU amongst adolescents on anti-retroviral therapy (ART). The 
study will benefit the HIV program in Gaborone, Botswana in contributing to developing 
effective strategies to retain adolescents on ART.   
1.4 Thesis chapter outline 
In Chapter 2 the literature on the subject of LTFU will be examined with emphasis on studies 
conducted in Eastern and Southern Africa. The review will focus of definitions of LTFU on 
ART, rates and factors associated with LTFU on ART in general and also specifically amongst 
the adolescent population. 
Chapter 3 presents the methodology of the study. The aim of the study is to determine the rates 
and factors associated with LTFU amongst older adolescents. The study design, setting, study 
http://etd.uwc.ac.za/
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population, sampling techniques, data collection and analysis are outlined. A research ethics 
statement is also included.  
In Chapter 4 the results of the study are presented. The data is presented as univariate, bivariate 
and multivariate analysis. The results are presented in tabular form and also described.  
Chapter 5 discusses the findings of the study, making comparisons with similar studies 
conducted in comparable settings 
Chapter 6 concludes the study and also makes recommendations in line with the research 
findings.  
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                                       CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
One of the greatest threats to the success of global ART programs is the persistent attrition of 
patients from such programs, also referred to as lost-to-follow-up (LTFU).  This chapter will 
explore the different definitions of LTFU on ART and explain the choice of the definition used 
for this study. This chapter is also an overview of the rates and factors associated with LTFU in 
broader age categories and patient groups. Lastly factors associated with LTFU (on ART), 
particularly amongst adolescents is examined. 
2.2 Definition of Lost-To-Follow Up 
Due to the initial high morbidity and mortality associated with HIV-related illnesses, outcomes 
of success of HIV care programs have been traditionally measured by the prevalence of 
opportunistic infections and mortality rates.  However as more people living with HIV readily 
access ART and remain alive, retention in care as estimated by LTFU rates has become more 
relevant in measuring program effectiveness (Brinkhof, Dabis & Myer, 2008). A standardized 
definition of LTFU is therefore required for comparative reviews of data on patient retention 
from different ARV programs. This will make it more feasible to compare attrition rates in ART 
programs within and between countries. 
  A review of HIV medical literature reveals a variety of definitions of LTFU. Shepherd, Blevins 
and Vaz (2013) found 17 different definitions used for LTFU of patients on ART in their reviews 
of studies. Using these different definitions of LTFU, the rates in this review varied from 22% to 
84% (Shepherd, Blevins & Vaz, 2013). The definitions differed in the focus on the following 
indicators: duration on ART; time measured from last visit vs missed visit for ART and the visit 
for last encounter (clinic, laboratory or pharmacy). A study which analyzed data from ART 
programs in Sub-Saharan Africa also showed that by using different LTFU definitions, the rates 
vary considerably, making it difficult to compare programs (Brinkhof, Dabis & Myer, 2008). For 
example in the Brinkhof et al (2008) study LTFU rates of 9, 3% were estimated when one 
definition was used, compared to 1, 3% with an alternative definition. The former definition 
included amongst the LTFU, patients who were initiated on ART and never returned to the clinic 
after only one visit, whilst the alternative definition did not.  
http://etd.uwc.ac.za/
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After an analysis of ARV programs in 19 countries in 2011, researchers recommended that the 
definition of LTFU should be that “180 days or more have elapsed since the patient's last clinic 
visit” (Chi, Yiannoutsos, Westfall, Newman & Zhou J, 2011: 10). Using this 180 day threshold, 
the rates of LTFU in countries ranged from 3% to 45%. The researchers reported that much of 
the variation in the definition of LTFU occurred when information was collected at facility level, 
with measures of LTFU used ranging between 58-383 days since the patients’ last visits (Chi, 
Yiannoutsos, Westfall, Newman & Zhou J, 2011). The current WHO definition of LTFU is a 
patient on ART who is not seen at the clinic “90 days after the last scheduled appointment” 
(WHO, 2011:26). The appointment in this definition is considered to be either a clinic or 
pharmacy visit. This WHO definition allows for comparison of ART programs within and 
between different countries. In Botswana the WHO definition is used in defining lost-to-follow-
up (Farahani, Vable & Lebelonyane, 2013).  
2.3 Rates and reasons of Lost-To-Follow-Up on ART 
2.3.1 Attrition rates in ART care 
Studies on retention in care in ART programs have become increasingly relevant since most 
countries in sub-Saharan Africa have rapidly expanded and enrolled more patients on treatment 
than before. A systemic review of ART programs in sub-Saharan Africa showed that the 
retention of patients in programs after 2 years, ranged between 46% and 85% in different 
countries (Rosen, Fox & Gill, 2007). The study accepted the varying definitions of LTFU used 
by the different countries.  The major causes of attrition from ART care in this analysis was 
reported to be LTFU (56%), followed by death (40%). The remaining 4% was due to patients 
having discontinued their antiretroviral treatment, but remaining in care in the facility. The 
highest retention rate at 3 years after ARV initiation was in South Africa (87%) and the lowest 
was recorded in a study in Botswana (64%) (Rosen, Fox & Gill, 2007). However this review of 
percentages of attrition in these studies does not include an analysis of the factors associated with 
LTFU in these countries and does not report the rates of LTFU up in the sub-populations of 
pediatrics and adolescents. In this review of studies in African countries, death was a sizeable 
contributor to the LTFU patients.  
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This is supported by study conducted in Malawi that showed that of the patients who were 
reported to be LTFU, 50% had died, 23% were alive but not on treatment whilst 27% could not 
be traced and so their outcomes were unknown (Yu, Chen, Wang, Chang & Makombe, 2007). Of 
those who were found to be alive and traced, the majority (64%) had stopped treatment due to 
high transport costs in attending an ART facility. This study does not report the rates and reasons 
for LTFU, specifically amongst adolescents. This is despite the fact that children make up 
approximately 12% of the people living with HIV in Malawi (UNAIDS, 2015).  In a study 
conducted in South Africa which analyzed patients who were classified as LTFU while on ART 
found that, 31% had died, 25% were accessing treatment at other centers and 44% could not be 
located or had discontinued treatment (Dalal, MacPhail & Mqhayi, 2008). Those accessing 
treatment at other centers cannot be considered true LTFU, but rather indicates a need for better 
communication between centers on transfer of patients on ART out of one facility to another.  
In contrast to studies conducted in African countries, in a study done in the UK, deaths 
contributed to only 3% of patients who were classified as LTFU (Gerver, Chadborn, Ibrahim & 
Vatsa, 2010). In this UK study, 48% patients who were initially classified as LTFU had actually 
transferred to other sites without informing the initial sites.  In this study advanced 
immunosuppression as measured by low CD4 count was a key predictor of LTFU. Other 
predictors of LTFU in the same UK study was a detectable viral load (>400) at last clinic visit, 
earlier year of ART clinic registration and being a heterosexual African female. Similarly in a 
study conducted in New York of patients who were presumed to be LTFU, 2% had died 
(Udeagu, Webster, Bancour, Michel & Shepherd, 2013).  
2.3.2 Factors associated with LTFU 
This section provides an overview of the factors that influence patients on ART being LTFU, as 
reflected in peer reviewed literature. It will review the structural and psychosocial factors and 
also patient level factors, in particular immunological factors, virological status, adherence to 
ARV drugs, ARV drug regimens, WHO clinical status and tuberculosis history.  
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2.3.2 (a) Facility and psychosocial factors 
Facility level and psychosocial factors may affect retention in ART clinics. A qualitative study 
amongst adults on retention in ART care in South Africa showed that transport costs and time 
patients spent seeking treatment were significant barriers and possible contributors to LTFU 
(Miller, Ketlhapile, Rybasack-Smith & Rosen, 2010). In this study, HIV related stigma was not 
found to be a significant factor resulting in patients defaulting from treatment.  HIV-stigma was 
also not found to be a key factor affecting LTFU of adults on ART in a South African 
quantitative study (Evangeli, Newell, Ritcher & McGrath, 2014).  However, in contrast, in a 
qualitative study in Kenya conducted amongst an adolescent population living with HIV, HIV-
related stigma was found to be a compelling factor for LTFU (Wolf, Halpern-Felsher, Bukusi & 
Agot, 2014). In this study HIV- related stigma was mentioned as being experienced in the home, 
school and clinic settings. This may have resulted in poor clinical outcomes amongst adolescent 
compared to adults, as was shown by a retrospective analysis done in South Africa (Evans, 
Menezes & Mahomed, 2013).  
2.3.2 (b) Immunological factors 
There is conflicting evidence on whether there is an association between the immunological 
status (as measured by CD4 count) and LTFU amongst HIV positive persons on ART. A 
baseline CD4 is a measurement which is done on entry into care by a person living with HIV 
(CDC, 2016).  According to the WHO, a CD4 count of less than 350cells/µL is an indicator of 
significant immunosuppression and if less than 200cells/µL it indicates severe 
immunosuppression (WHO, 2005).  A retrospective review which was conducted in South Africa 
showed that the average CD4 count amongst LTFU patients on ART was low at 92cells/µL 
(Maskew, MacPhail, Menezes & Rubel, 2007).  A low CD4 count amongst LTFU patients was 
also noted in a study which was conducted in Tanzania, in which the mean CD4 count was 
122(67-180) cells/µL (Makunde, Francis & Kamugisha, 2012).  A case-control study conducted 
in Uganda also showed that a CD4< 200cell/µl was associated with LTFU amongst patients on 
ART, with the association greatest when the CD4 count was <50cell/µL (Okoboi, Diring, 
Persuad & Wangisi, 2015).  
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In a retrospective observational study conducted in South Africa a baseline CD4 count above 
200cells/µL was associated with becoming LTFU (Mberi, Dube, Kuonza & Nattey, 2015). In 
contrast, a baseline CD4 count of less than 200 was found to be a risk factor for LTFU amongst 
patients on ART in an Ethiopian study (Berheto, Haile & Mohammed, 2014). In contrast a 
different South African study showed no association between baseline CD4 count and LTFU 
(Shearer, Fox, Maskew, Sann & Long, 2013). Hence there is a need for further research to 
determine whether there is an association between baseline CD4 and LTFU whilst on ART. 
2.3.2 (c) Virological failure 
HIV Viral load is the measure of the amount of viral copies per ml of blood (AIDSMAP, 2017).  
According to WHO, virological failure is defined as two consecutive detectable viral load (VL) 
above 1000 copies/ml (WHO, 2016). Some studies have found an association between detectable 
VL and LTFU amongst patients on antiretroviral therapy. A cohort study conducted in South 
Africa found that a detectable VL was independently associated with LTFU, in multivariate 
analysis (Mberi, Dube, Kuonza & Nattey, 2015).  This was also evident in a case control study 
conducted in France (Ndiaye, Ould-Kaci, Salleron & Bataille, 2006). In this study the association 
with LTFU on ART was greatest with VL of >10 000 copies/ml at the time of LTFU. A 
retrospective evaluation of data from a PEPFAR funded program conducted in Nigeria for the 
years 2004 to 2012 showed that 71% of the LFTU patients had detectable VL, 6 months prior to 
LTFU (Meloni, Chang, Chaplan & Rawizza, 2014). This analysis showed a statistically 
significant association between VL and LTFU.  
2.3.2 (d) Adherence to ART medications 
Adherence to ART medications is vital in achieving viral suppression and optimizing health 
outcomes amongst PLHIV. Adherence to ART drugs of less than 95% is associated with a 
significant (61%) risk of treatment failure (UNAIDS/WHO, 2011). Some of the factors affecting 
adherence to ART are ARV drug side effects, pill fatigue, stigma and lack of community support 
(UNAIDS, 2014).  Hence it is important to investigate whether suboptimum adherence to ART is 
associated with LTFU in ART care. A case control study conducted in Ethiopia showed that 
adult patients with suboptimal adherence to ART of < 95% were 7 times more likely to be LFTU 
in ART care (Mergerso, Garoma, Etichia & Workineh, 2016). The link between poor ART 
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adherence and LTFU in ART care was also shown in a Nigerian study, in which patients with 
100% adherence to ART had a 64% lower risk of LTFU in ART care compared to patients with 
an adherence of <50% (Meloni, Chaplain, Chang, & Rawizza, 2014).  This association was also 
found in a study conducted in Kenya amongst HIV positive pregnant women, with patients 
having suboptimal adherence to ART being more likely to become LTFU in ART care (Clayden, 
2012). 
2.3.2 (e) Antiretroviral drug regimens 
Different ART regimens have varying side effects, which could possibly influence adherence to 
medication and default in ART care follow up visits by patients.  ART side effects have been 
shown to be a contributing factor in LTFU amongst PLHIV on ART (Dalal, MacPhail & 
Mqhayi, 2008). Some LTFU to ART care studies have shown statistically significant differences 
in LTFU rates depending on the ART regimen of a patient. An Ethiopian study showed that 
patients on AZT/3TC/NVP regimen were at more than 3-fold increased risk of LTFU compared 
to those on d4T/3TC/NVP (Tardese & Haile, 2014). The authors suggested that the difference 
may be explained by the fact that AZT-based regimens are associated with higher rates of side 
effects.  Another Ethiopian study found that patients with a history of a regimen substitution had 
a 5- fold higher risk of LTFU compared to those with no regimen substitution (Berheto, Haile & 
Mohammed, 2014). However this evidence that certain regimens that have higher rates of 
adverse side effects are associated with a higher risk of LTFU is not consistent with the findings 
from some other studies. A  Nigerian study showed that patients on TDF/FTC/EFV where more 
likely to be LTFU than those on AZT/3TC/EFV regimen (Meloni, Chaplain, Chang & Rawizza, 
2015). Additionally another Nigerian study also found that patients on TDF-based regimens were 
at a higher risk of LTFU compared to those on AZT-based regimens (Eguzo, Lawal, Umezurike 
& Eseigbe, 2015). This is despite TDF-based regimen being associated with significantly less 
adverse side effects compared to AZT-based regimens (Bygrave, Ford, van Cutsem & 
Hilderbrand, 2011).  Therefore, there is conflicting evidence on whether the difference of LTFU 
rates on between regimens could be explained by adverse effects associated with these particular 
regimens. 
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2.3.2 f) WHO clinical staging   
Clinical staging of HIV/AIDS may impact on LTFU in care among those on ART. People living 
with HIV are clinically staged to determine the extent of progression of the illness as per WHO 
guidelines clinical stages I, II, III and IV. Stage IV indicates the most advanced disease stage 
(WHO, 2015). Several studies have shown that patients on ART with a more advanced WHO 
clinical stage are associated with LTFU in ART care. In a case-control study conducted in 
Ethiopia, patients classified as WHO stage IV were twice as likely to be LTFU in ART care 
compared to those classified with WHO clinical stage I illness (Mergerso, Garoma, Eticha & 
Workineh, 2016). This was also evident in a Togolese study, with those classified as WHO III/IV 
being associated with greater LTFU in ART care compared to those classified as WHO stage I/II 
(Saka, Landoh & Patassi, 2013).  This association was also found in a South African cohort 
study, in which patients with a baseline WHO stage of III/IV were shown to have a higher risk of 
LTFU in ART care compared to those classified as stage I/II (Mberi, Dube, Kuonza & Nattey, 
2015).  However in contrast one Ethiopian study showed that patients with a baseline WHO 
stage III/IV were less likely to be LTFU (Berheto, Haile & Mohammed, 2014).  
2.3.2 (g) Tuberculosis 
Tuberculosis (TB) is a common HIV-related illness particularly in developing countries. 
According to WHO, people living with HIV are up to 31 times more likely to develop TB 
compared to those who are HIV negative (WHO, 2017). There is some evidence that TB is 
associated with LTFU amongst patients on ART. In a study conducted in Ethiopia, patients on 
ART with proven pulmonary TB were approximately twice as likely to be LTFU in ART care 
compared to those without TB (Tadesse & Haile, 2014). According to the study, the higher risk 
of LTFU was possibly due to adverse drug reactions associated with TB treatment drugs, which 
are more prevalent in patients also on ART medication. A study conducted in Kenya also showed 
that there were high rates of LTFU amongst TB-HIV patients on ART (Tayler-Smith, Zachariah, 
Manzi & Kizito, 2011). In this study there was 14% LTFU amongst TB patients who were 
commenced on ART.  A cohort study in India found there was an attrition rate of 47% amongst 
patients who were diagnosed with TB whilst on ART compared with 35% among those without 
TB (Alvarez-Uria, Naik, Pakam & Midde, 2013). However the attrition rates amongst patients 
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who were diagnosed and treated for TB before ART commencement, the attrition rates were 
similar to patients without previous TB (36% vs 35%).  
2.3.2 (h) Other factors 
A study conducted in South Africa in ART community clinics run by Faith Based Organizations 
in which the rates of LFTU was 6% at 6 months after ART initiation, found that both pregnancy 
and lower CD4 count were associated with higher risk of LTFU in ART care (Wang, Losina & 
Stark, 2011). A similar case-control study conducted in Kenya also showed pregnancy to be 
associated with LTFU (Karche, Omondi, Odera, Kanz & Harms, 2007). However unlike in the 
South African study, CD4 count was not found to be a contributing factor to ART care LTFU. 
The Kenyan study also found lower educational status to be significantly associated with LTFU 
whilst on ART. This was supported by a Ugandan study which also showed an association 
between lack of formal education and LFTU in ART care (Burkley, Weiser & Fehmie, 2015). 
However in contrast, a multi-centred South African study amongst pregnant women on ART 
found no association between level of education and LTFU in ART care (Onoya, Sineke, 
Brennan & Fox, 2014). 
2.4 Loss-to-follow up amongst adolescents on antiretroviral therapy 
Adolescence is a period of physiological and social transition from childhood to adulthood and is 
associated with less dependence on caregivers.  Adolescents on ART, particularly those who 
have been on treatment since childhood, begin to take extra responsibility especially in taking 
their medications and attending clinic consultations. Due to these factors, adolescents might be at 
greater risk of defaulting treatments and becoming LTFU, as supervision from caregivers 
becomes less.  A study which analyzed data from 9 ART sites in Southern Africa showed that 
ART adherence rates where lower amongst adolescents (11-19 years) when compared to adults 
(Nachega, Hislop, Nguyen & Dowdy, 2010). Barriers to adherence to treatment amongst 
adolescents include fear of disclosure and anticipated HIV-related stigma (Denison, Banda, 
Dennis & Packer, 2015).  
A study conducted in Ethiopia showed adolescents were associated with increased risk of LTFU. 
The study found that being an adolescent, having had a regimen substitution, being in good 
health and a low baseline CD4 were associated with higher rates of LTFU (Berheto, Haile & 
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Mohammed, 2014).  Berheto et al. (2014) also showed that adolescents 11-19 years were at a 
higher risk of LTFU compared to children ≤10 years old.  The adolescents were also twice as 
likely to be LTFU compared to adult patients in the same study. A study conducted in Nigeria 
showed no difference in lost-to-follow-up rates between adolescents and younger children 
(Ojikutu, Higgings-Biddle, Greeson & Phelps, 2014). Therefore contrasting findings exist in 
literature on whether adolescents are at higher risk to LTFU compared to children, but the 
findings are generally in the direction of increased LTFU for adolescents. 
A retrospective study conducted in South Africa compared LTFU between adolescents and 
adults (Evans, Menezes & Mohamed, 2013). It found that middle and older adolescents (15-19 
years) were about 2-fold most likely to be LTFU, whilst adolescents (10-14 yrs) were 2 times 
less likely to be LTFU when compared to adults. The middle and older adolescents also had 
other poorer treatment outcomes such as virological failure. A study in Ethiopia showed that 
middle and older adolescents and young adults (15-24 yrs) where about 6 times more likely to be 
LTFU compared to 25-34 years age category (Mergerso, Garoma, Eticha & Workineh, 2016). 
Quality of medical care may influence LTFU amongst adolescents on ART. A Nigerian study 
showed that provision of high quality care to children and adolescents living with HIV, was 
associated with reduced risk of LTFU (Ojikutu, Higgings-Biddle, Greeson & Phelps, 2014). In 
this study, quality of care measures that reduced the likelihood of LTFU were adherence 
counseling and adherence measurements (pill counts) at clinic visits. These factors are important 
in reducing LTFU amongst HIV patients on antiretroviral therapy generally. A retrospective 
study also showed that patients who received higher levels of adherence support were associated 
with less risk of LTFU (Etienne, Burrows, Osotimehim, Macharia, Hossain, Redfield & 
Amoroso, 2010). The LTFU rates in this study were approximately 19%.  Adolescents 
particularly those on treatment since childhood can have medication fatigue which can result in 
them defaulting from ART (Hogdson, Ross, Haamujompa & Gitau-Mburu, 2012).  
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2.5 Summary of Literature review 
Lost-to-follow up in ART care is a threat to the control of the HIV epidemic. There are various 
definitions used for LTFU on ART, however most studies use the WHO (2011) definition of 
“Not seen in the clinic at least 90 days from last appointment date”. There is significant research 
in this area, although studies particularly focusing only the adolescent population are few. 
Middle and late adolescents may be a particularly vulnerable group for LTFU. There is generally 
evidence that LTFU is associated with clinical variables associated with poor adherence to ART 
drugs.  
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CHAPTER 3: METHODOLOGY 
3.1 Introduction 
Chapter 3 presents an overview of the methodology used in this study. It includes a description 
of the aim and objectives, the study design, setting, population and sampling procedure, the study 
analysis, ethics considerations and the study limitations. 
3.2 Aim 
The aim of this study was to investigate the percentage and the causes of lost-to-follow-up 
amongst a sub-population of HIV positive middle and late adolescents on antiretroviral therapy 
in an urban health care facility in Botswana. 
3.3 Objectives 
Its objectives were, at the Baylor Clinic in Gaborone, for the period 2010-2015: 
1. To identify HIV positive middle and late adolescents on ART who were lost-to-follow-up 
and those retained on ART. 
2. To describe the rates of lost-to-follow-up amongst HIV positive middle and late 
adolescents on antiretroviral therapy (ART). 
3. To compare HIV and ART related variables amongst LTFU and non-LFTU middle and 
late adolescents on ART. 
3.4 Study type/design 
The study was a retrospective observational study in which data from a sample of adolescent 
patients that were lost-to-follow-up and those who were not lost-to-follow-up (on ART and 
retained in care) were analyzed. Those LTFU and those not LTFU were selected from the same 
clinic for the same period.  
3.5 Study site 
The study site was Botswana-Baylor children’s and adolescents HIV clinic, located in the city of 
Gaborone in Botswana. It provides comprehensive HIV preventive, curative and psychosocial 
services. The clinic is run by Baylor-Botswana, a partnership between Ministry of Health of 
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Botswana and Baylor College of Medicine from Houston, USA. The clinic has about 2200 
children, adolescents and young adults currently on anti-retroviral therapy.  Of these 1300 are 
between the ages 10- 19 years. The clinic staff is composed of two pediatricians, four medical 
officers, nine trained nurse prescribers, three pharmacy officers, a social worker, a psychologist, 
a monitoring and evaluation officer and a dietician. The clinic also hosts scholars and pediatric 
and adolescent specialists from Baylor College of Medicine for various durations. 
3.6 Study population 
The study population comprised all adolescents aged 15-19 years who attended the Botswana-
Baylor clinic in Gaborone, Botswana from January 1
st
 2010 to 31
st
 December 2015 with 
confirmed HIV infection and on antiretroviral therapy.  The middle and late adolescent 
population group was chosen due to anecdotal evidence that defaulting from ART is more 
common as supervision from caregivers reduces.  
3.7 Sampling  
A probability sampling method was used in the study. In probability sampling, all the patients in 
the sampling frame have an equal probability of being selected. The specific type of sampling 
method used was simple random sampling. Simple random sampling was straightforward to 
apply as there was a readily available list of adolescent patients who were ever LTFU in ART 
care.  
The sample size was calculated using Epi-Info 7 software. Epi-info stat calculator was used to 
calculate the sample size needed to illustrate a difference in follow up on ART. A 2-sided 
confidence level of 95% was used, with a power of 80%, ratio of those LTFU to those not LTFU 
of 1:1. A hypothetical proportion of those not LTFU with exposure 40% (CD4<350) and least 
extreme odds ratio to be detected =2. There were 133 LTFU and 133 not LTFU selected. 
For the purposes of this study the WHO (2011) definition of not seen in the clinic for 90 days 
after the last scheduled appointment was used. The scheduled appointment was considered as 
either a clinic or pharmacy encounter. The LTFU register in the clinic was accessed and patients 
meeting the criteria as outlined in the inclusion criteria were selected i. e adolescent patients aged 
15-19 years who were on ART, who were not seen in the clinic/pharmacy for at least 90 days 
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after the last scheduled appointment during the period 2010-2015. From this list the sample was 
selected by using random sampling software. Those not LTFU were selected at 1:1 with those 
LFTU, from adolescents (15-19 years) on ART who are retained in care at the same time of those 
LTFU.  Those not LFTU were matched for sex, age and year of lost-to-follow (for those LTFU).  
Patient records with no relevant data (demographic and clinical) were excluded and the next 
study subject in the list was selected as a replacement.  
3.8 Inclusion and exclusion criteria 
3.8.1 Inclusion criteria for LTFU 
HIV positive 
Middle and late adolescent 15-19 years on ART. 
Not seen in the clinic at least 90 days from last appointment date. 
3.8.2 Exclusion criteria for those LTFU 
Insufficient data available in the IPMS (integrated Patient Management System) at the clinic 
3.8.3 Inclusion criteria for those not LFTU 
HIV positive 
Middle and late adolescent 15-19 years, on ART 
Non- defaulters from ART 
Exclusion criteria were the same as for those LTFU. 
3.9 Data collection procedures 
Quantitative data were collected from the patient records in the Patient Management Information 
System (PIMS) at the clinic. PIMS is software in the clinic, which has all the relevant patient 
data i.e. demographic data, pharmacy encounters, laboratory data and patient consultation 
summaries.   
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The data collected was age, gender, date of enrollment in care, date of ART initiation, date of 
lost-to-follow-up (for those LTFU) and date of appointment kept (for those not LTFU), baseline 
CD4 count, CD4 count prior to lost-to-follow-up (those LTFU) and a similar date for keeping an 
appointment for those not LTFU, viral load prior to lost-to-follow-up and a similar date for those 
not LTFU, WHO stage (those LTFU) and a similar date for those not LTFU, ART regimen, viral 
load at last 2 visits, history of TB-HIV co-infection, adherence measurements by pill counts (in 
the year prior to LTFU or retention in care)  and relationship with primary care giver. 
3.10 Data collection tool  
A standardized form was used to collect the data (See Appendix 1). For operational definitions of 
data to be extracted, see Appendix 1 a). I collected data as the investigator and patients were 
identified by a unique study number.  
3.11 Validity of study 
To improve the validity of the study there were clear definitions of the LTFU and not LTFU and 
risk factors for LFTU. The data collection tool was piloted using other patients’ records, not 
included in the study. During this process it was noted that information baseline WHO staging 
(at ART initiation) of most patients was not available and hence was taken off the tool. However 
WHO staging at LFTU was consistently available.  The data collection tool was also scrutinized 
by an HIV expert to ensure content validity. During data analysis, the researcher (myself), who 
analyzed the data was blinded as to which study patient numbers were LTFU and not LTFU.  
3.12 Reliability of study 
To improve reliability of the study, the data collector verified all the data collected. Data 
collected was also verified by a different medical practitioner trained to complete the data 
collection tool. There was consistency in data collected by the two data collectors i.e. observer 
variation was minimal hence reducing bias.  
3.13 Generalizability of study 
The study findings were extrapolated to Botswana-Baylor Clinic, amongst mid and older 
adolescents (15-19 years) and not to any other setting and population.  
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3.14 Data analysis  
Data were analyzed with Epi-Info 7 software. Univariate analysis was conducted initially, to 
describe distributions. The software was used to conduct bivariate analysis so as to calculate the 
odds ratio for each variable collected and the confidence interval and P-value to determine 
statistical significance between the outcome and exposure variables. The outcome variable was 
LTFU in ART care. Bivariate analysis with EPI-info 7 was conducted to determine if there was 
any significant association between LTFU and the exposure variables. Multivariate logistic 
regression was used to identify independent associations between LTFU and a combination of 
risk factors associated with the odds of LTFU. 
3.15 Ethics statement 
The study involved a vulnerable population who are HIV positive and a large number of whom 
were less than 18 years.  However minimal harm was expected as the study was a record review, 
rather than involving engagement with patients. The data were anonymized, through patients 
being assigned study numbers instead of names or folder numbers being recorded prior to 
extraction. Consent was not a requisite for this study as routine anonymized data was used. 
The study was not aimed at directly benefitting those patients from whom data is collected as 
data was anonymized and individual patients were not being specifically followed up during the 
study. However the study aimed to benefit HIV positive adolescents on ART at the clinic in 
general. The findings of this study are being used to make recommendations to reduce rates of 
LTFU at the ART clinic. This can contribute to improving health outcomes amongst adolescents 
living with HIV by reducing morbidity and mortality rates.  
The study ensured that there was fair selection of participants through random sampling 
techniques. No particular social group/class was targeted. Ethnicity and race was not used to 
select participants. During the process of data collection anonymity was ensured by not recording 
any individual identifying information and confidentiality was strictly maintained. Ethics 
approval for conducting the research was obtained from the Baylor Clinic Management and IRB 
(see attached letter, Appendix 2). Ethics clearance for the retrospective studies and data analysis 
in the clinic were covered by a medical audit permit from Health Research and Development 
Committee (HRDC) Board of the Ministry of Health, Botswana. The research proposal was 
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granted ethics approval by the University of the Western Cape Higher Degrees and Biomedical 
Research Ethics Committee (Ethics reference number: BM/16/5/30) 
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 CHAPTER: 4 RESULTS 
Baylor Clinic had 895 adolescents (15-19 years) who had ever been enrolled on ART as at end of 
September 2017. This excluded deaths and transfer-outs.  Of these 41 were LTFU on ART, 
giving a current LTFU rate of 4.6%.  
The eligible population for the study was 316 adolescents (15-19 years) who were ever lost-to-
follow-up in the period 2010-2015. Using simple random sampling, 133 those LFTU were 
selected. The 133 not LTFU were selected from adolescents who were retained in care matching 
the year of LTFU, age and sex for those LTFU.  During data collection 5 LTFU and 3 not LTFU 
had inadequate data and were replaced by the next subject in the study population. It was noted 
during data collection that almost all records had missing WHO staging data at the time of 
LTFU, hence this was excluded from the analysis. However the WHO staging at the time was 
ART initiation was available.  
As can be seen in Table 1, in the total sample (n=133) there were slightly more females (53%) 
than males (47%). As those LTFU and those not LTFU were matched by sex, both groups had 
similar proportions of males and females. The majority of those in the whole sample (55%) were 
in the older age group (18 and 19 years) at the time of LTFU. The median age of the sample was 
18 years. The age distribution of those LTFU and those not LTFU were similar, due to the two 
groups being age-matched in the selection of the samples.  Pertaining to ART regimens, a slight 
majority was on PI-based ART
3
 (51.9%), while the remaining patients were on a Non-
Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based HAART (Efavirenz and 
Nevirapine). The most common regimen was Combivir/Aluvia accounting for 26.3%. There 
were no patients on salvage regimens of ART.  
In terms of CD4 count, a greater proportion of the respondents had lower CD4 counts (<350) at 
baseline compared to at the time of LTFU (43.6% vs 25.9%).  This is expected as ART usually 
results in improved immunity which is measured by CD4 count. Most study patients had 
advanced HIV disease with 71.8% having either a WHO stage 3 or 4 clinical condition at the 
time of ART initiation. As mentioned, data on WHO staging at the time of LTFU was not 
                                                          
3
 A PI (Protease Inhibitor-based) regimen is an alternative ART regimen which is associated with more adverse 
gastrointestinal side effects and more pill burden compared to NNRT-based regimen (AIDS INFO, 2017). The PI 
used mostly at Baylor clinic is Aluvia. 
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available in the records.  The majority of the respondents (59%) had a biological parent as the 
caregiver, whilst 43% were under the care of relatives and 3.4% were in an orphanage.  
Adherence measured by pill counts was relatively good with 91% having an adherence of above 
80%, with 68% achieving an optimal adherence above 95%.  Previous history of Tuberculosis 
was found in 51 of the 266 respondents (19%). The majority (84%) of the TB cases had 
pulmonary disease, whilst the most common type of extra-pulmonary disease was Lymph node 
TB (7.8%).  Virological failure defined as VL > 1000 copies/ml was found in 39.5% of the 
respondents with 5% having VL>100 000, which is usually associated with very poor adherence. 
Table 1: Socio-demographic and clinical characteristics of respondents (n=266) 
 Frequency (n) Percentage (%) 
Gender 
Male 
Female 
 
126 
140 
 
47.4 
52.6 
Age 
15 
16 
17 
18 
19 
 
42 
36 
42 
44 
102 
 
15.8 
13.5 
15.8 
16.5 
38.4 
CD4 count Baseline 
0-199 
200-349 
350-499 
>500 
 
49 
67 
69 
81 
 
18.4 
25.2 
25.9 
30.5 
 
 
CD4 at LTFU 
0-199 
200-349 
350-499 
>500 
 
21 
48 
51 
146 
 
7.9 
18.0 
19.2 
54.9 
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ART Regimen 
Combivir/Aluvia 
Truvada/Aluvia 
Abacavir/Lamivudine/Aluvia 
Combivir/Efavirenz 
Conbivir/Nevirapine 
Abacavir/Lamivudine/Efavirenz 
Abacavir/Lamivudine/Nevirapine 
Atripla 
Truvada/Nevirapine 
 
70 
47 
21 
44 
27 
15 
18 
17 
7 
 
26.3 
17.7 
7.9 
16.5 
10.2 
5.6 
6.8 
6.4 
2.6 
WHO staging at ART initiation 
Stage 1 
Stage 2 
Stage 3 
Stage 4  
 
31 
44 
83 
108 
 
11.6 
16.5 
31.2 
40.6 
Caregiver 
Parent 
Uncle/Aunt 
Grandparent 
Orphanage 
Other 
 
157 
73 
24 
9 
3 
 
59.0 
27.5 
9.0 
3.4 
1.1 
 
 
 
 
Adherence 
<60% 
60-80% 
80-95% 
>95% 
 
 
11 
13 
61 
181 
 
4.1 
4.9 
22.9 
68.1 
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Viral load 
                <1000 copies/ml 
        1000- 9999 copies/ml 
10 000- 100 000 copies/ml 
           >100 000 copies/ml 
 
161 
42 
49 
14 
 
60.5 
15.8 
18.4 
5.3 
Tuberculosis Cases 
Pulmonary TB 
Lymph node TB 
Pleural TB 
TB meningitis 
TB abdomen 
 
43 
4 
2 
1 
1 
 
84.3 
7.8 
3.9 
2.0 
2.0 
 
Table 2 is a summary of the proportion of those LTFU and not LTFU, associated with a specific 
independent variable. Nearly half (48%) of those LTFU had a low baseline CD4 (<350) 
compared to those not LTFU (39%). There was also a higher proportion (38%) of those LTFU 
with a low CD4 at the time of LTFU compared to those not LTFU (14%). Virological failure 
VL>1000 was also common amongst those LTFU (61% vs 18%). The WHO staging at ART 
initiation was similar amongst those LTFU and those not LTFU (74% vs 69%), whilst more of 
those LTFU had a history of past TB (24% vs 14%).  A greater proportion of those LTFU were 
on PI-based ART compared to those not LTFU (62% vs 41%), with also more of those LTFU 
having suboptimal ART adherence (47% vs 17%). A biological parent being the primary 
caregiver was comparable amongst the two groups (42%vs 40%).  
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Table 2: Clinical variables and their association with LTFU, Baylor Clinic (n=133) 
VARIABLES LTFU 
N (%) 
Not LTFU 
N (%) 
Baseline CD4 
<350cells/ml 
≥350cells/ml  
 
64 (48) 
69 (52) 
 
52 (39) 
81 (61) 
CD4 (LTFU) 
<350cell/ml 
≥350cells/ml  
 
50 (38) 
83 (62) 
 
19 (14) 
114 (86) 
VL 
≥1000 copies/ml 
<1000 copies/ml  
 
81(61) 
52 (39) 
 
24 (18) 
109(82) 
WHO  Stage 
(Baseline) 
III/IV 
 
I/II 
 
 
99 (74) 
 
34 (26) 
 
 
92 (69) 
 
41 (31) 
TB history 
Present 
Absent  
 
32 (24) 
101(76) 
 
19 (14) 
114 (86) 
ART regimen 
PI- based 
NNRTI- based  
 
83 (62) 
50 (38) 
 
55 (41) 
78 (59) 
 
 
Caregiver 
Non-Parent 
Parent  
 
56 (42) 
77 (58) 
 
53 (40) 
80 (60) 
Adherence 
<95% (Suboptimal) 
≥95% (Good)  
 
63 (47) 
70 (53) 
 
22 (17) 
111 (83) 
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Table 3 is a summary of associations between LTFU and different independent exposure 
variables that were tested using bivariate analysis. The table shows the crude odds ratio for each 
variable and also the p-value to show statistical significance. 
In the bivariate analysis there were statistically significant associations between CD4 count (at 
LTFU) and LTFU from ART care, crude odds ratio of 3.61(95% CI: 1.98-6.57 P value<0.001). 
There was however no significant association between CD4 count at ART initiation and LTFU 
from ART care (OR=1.44 (95% CI: 0.89-2.35 p=0.139). Presence of virologic failure was 
statistically significantly associated with LTFU in ART care, with adolescents with VL >1000 
copies/ml having about 7 times the odds of being LTFU compared to those adolescents with 
VL<1000 copies/ml (OR=7.07(95% CI: 4.03-12.41 p<0.001). Past history of Tuberculosis was 
also a predictor of LTFU (OR= 1.90 (95% CI: 1.01-3.56 p<0.005). 
The adolescents who were on PI-based ART regimen had about 2 times the odds of being LTFU 
on ART compared to those on NNRTI-based regimens OR=2.35(95% CI 1.43-3.85 p<0.05). In 
this study having a suboptimal adherence (<95%) to ART drugs was also a strong predictor of 
LTFU, OR= 4.54(95% CI 2.57-8.03) p<0.001).  
WHO stage at the time of ART initiation was not associated with LTFU in bivariate analysis 
(OR=1.29(95% CI 0.75-2.21 p=0.342) and so was not included in the model for multivariate 
analysis. The WHO staging at the time of LTFU was not available in the patients’ records and 
therefore was not available for analysis. As there was also no significant difference in the 
prevalence of LTFU amongst adolescents with a biological parent as the primary caregiver 
compared to those with a non-parent as the caregiver (OR=1.09 (95%CI 0.67-1.79 p=0.709) this 
was therefore also excluded from multivariate analysis. 
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Table 3: Clinical variables and their association with LTFU (Bivariate analysis) (n=133) 
VARIABLES LTFU 
N (%) 
Not LTFU 
N (%) 
Crude odds ratio 
(95% CI)  
p-value 
Baseline CD4 
<350cells/ml 
≥350cells/ml  
 
64 (48) 
69 (52) 
 
52 (39) 
81 (61) 
 
1.44(0.89-2.35) 
Ref category 
 
0.139 
CD4 (LTFU) 
<350cell/ml 
≥350cells/ml  
 
50 (38) 
83 (62) 
 
19 (14) 
114 (86) 
 
3.61(1.98-6.57)  
Ref category 
 
<0.001* 
Viral Load 
≥1000 
<1000 
 
 
81(61) 
52 (39) 
 
24 (18) 
109(82) 
 
7.07(4.03-12.41) 
P<0.001 
Ref category 
 
<0.001* 
WHO  Stage 
(Baseline) 
III/IV 
 
I/II 
 
 
99 (74) 
 
34 (26) 
 
 
92 (69) 
 
41 (31) 
 
 
1.29(0.75-2.21) 
Ref category 
 
 
0.342 
 
 
TB history 
Present 
Absent  
 
32 (24) 
101(76) 
 
19 (14) 
114 (86) 
 
1.90(1.01-3.56) 
Ref category 
 
0.045 
 
ART regimen 
PI- based 
NNRTI- based  
 
83 (62) 
50 (38) 
 
55 (41) 
78 (59) 
 
2.35(1.43-3.85) 
Ref category 
 
0.007* 
Caregiver 
Non-Parent 
Parent  
 
56 (42) 
77 (58) 
 
53 (40) 
80 (60) 
 
1.09(0.67-1.79)  
Ref category 
 
0.709 
 
Adherence 
<95% 
(Suboptimal) 
≥95% (Good)  
 
 
63 (47) 
70 (53) 
 
22 (17) 
111 (83) 
 
4.54(2.57-8.03)  
Ref category 
 
 
<0.001* 
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Table 4 is the summary of significant associations that were tested with multivariate analysis. 
The variables CD4 count (at LTFU), viral load, past TB, ART drug regimen and adherence 
which were found to be significantly associated with LTFU in the bivariate analysis were 
analyzed to determine if they remained independently associated with LTFU.  
Virological failure was found to be an independent predictor of LTFU on ART amongst 
adolescents with an adjusted OR=4.97 (2.63-9.39) P<0.001. Suboptimal adherence was also 
found to be an independent predictor of LTFU in multivariate analysis, adjusted OR=3.74(2.00-
7.01) P<0.001 
Past TB history, CD4 count (at LTFU) and ART drug regimen were not found to be predictors of 
LTFU in the multivariate analysis. 
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Table 4: Clinical variables and their independent associations with ART LTFU 
(Multivariate analysis) (n=133) 
 
 
VARIABLES LTFU 
N (%) 
Not LTFU 
N (%) 
Crude odds ratio 
(95% CI) P-value 
Adjusted odds 
ratio(95% CI)  
P-value 
CD4 (LTFU) 
<350cell/ml 
≥350cells/ml  
 
50 (38) 
83 (62) 
 
19 (14) 
114 (86) 
 
3.61(1.98-6.57)  
Ref category 
 
1.56 (0.76-3.20) 
P=0.2207 
Ref category 
VL 
≥1000 
copies/ml 
<1000 
copies/ml  
 
 
81(61) 
52 (39) 
 
24 (18) 
109(82) 
 
7.07(4.03-12.41) 
P<0.001 
Ref category 
 
4.97 (2.63-9.39) 
P<0.001 
Ref category 
TB history 
Present 
Absent  
 
32 (24) 
101(76) 
 
19 (14) 
114 (86) 
 
1.90(1.01-3.56) 
P=0.045 
Ref category 
 
1.91 (0.93-3.96) 
P=0.079 
Ref category 
ART regimen 
PI- based 
NNRTI- based  
 
83 (62) 
50 (38) 
 
55 (41) 
78 (59) 
 
2.35(1.43-3.85) 
Ref category 
 
1.49(0.82-2.68) 
P=0.1827 
Ref category 
Adherence 
<95% 
(Suboptimal) 
≥95% (Good)  
 
 
63 (47) 
70 (53) 
 
22 (17) 
111 (83) 
 
4.54(2.57-8.03) 
P<0.001 
Ref category 
 
3.74(2.00-7.01) 
P<0.001 
Ref category 
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Results summary 
The study results in the bivariate analysis showed that low CD4 (<350cell/mm
3
) at LFTU, 
detectable VL (of >1000), past history of Tuberculosis, PI-based ART regimen and suboptimal 
adherence (<95%) were significantly associated with LTFU. However in multivariate analysis 
only detectable viral load and suboptimal adherence were found to be independent predictors of 
LTFU.  Middle and older adolescent patients who were LTFU were about 5 times as likely to 
have a detectable VL and almost 4 times more likely to have suboptimal adherence than those 
not LTFU.   
In the next chapter the findings in this study will be discussed and compared with existing 
literature on the subject on LTFU on ART amongst the adolescents living with HIV. The 
discussion will focus on similar studies done in sub-Saharan Africa where the HIV epidemic is 
comparable to Botswana.  
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                                           CHAPTER 5: DISCUSSION 
The study is one of the few LTFU studies aimed to investigate the proportion of and factors 
associated with LTFU amongst middle and late adolescents on ART at Botswana-Baylor clinic 
to be conducted amongst the adolescent population in the country. This is despite there being 
evidence that clinical outcomes in this age category are poor.  The current LTFU rate amongst 
adolescents (15-19yrs) at the clinic is reported to be 4.6%. This is considerably lower when 
compared to the 12%, which was reported in public ART clinics in Botswana amongst all age 
categories (Farahani, Vable & Lebelonyane, 2013). The possible explanation for this difference 
is that a multi-disciplinary team, which has doctors, trained nurses, a psychologist and social 
workers providing intensive adherence assessments and support at this particular clinic.  This is 
supported by evidence by Ojikutu, Higgins-Biddle, Greeson and Phelps (2014), which showed 
that clinics providing adherence counseling and adherence measurements had low LTFU rates. 
In addition the clinic has a Teen Club, whereby teenagers living with HIV meet once every 
month and discuss topics such as medication adherence, stigma, disclosure, sexual and 
reproductive health and human rights. These services are not readily accessible in public sector 
clinics in Botswana. The clinic is also a site where there are significant research activities; hence 
the patients are exposed to regular adherence information.  
The majority of those LTFU (74%) and those not LTFU (69%) had advanced HIV disease 
(WHO III/IV) at ART initiation. This was also found in a study done in Ethiopia (76%), although 
it was amongst adult clients (Dessalegn, Tsadik & Lemma, 2015). This is in contrast to an 
analysis of program data from sub-Saharan countries which showed that at ART initiation 42%  
and  23% of patients had advanced HIV disease in 2006 and 2011 respectively (Lahuerta, Wu & 
Hoffman, 2014). It is however important to note that the majority of the sample population in 
this study commenced ART in childhood, when HIV is associated with rapid progression and 
advanced disease. An analysis done in 4 sub-Saharan countries had comparable findings to this 
study, whereby the proportion of children with WHO stage III/IV at ART initiation was 75% and 
62% for 2005 and 2010 respectively (Davies, Phiri, Wood & Wellington, 2013). 
In this study after bivariate analysis, CD4<350cell/mm
3
, detectable VL, past TB history, PI-
based regimen and suboptimal adherence where associated with higher risk of LTFU. However 
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in the multivariate model, only detectable viral load and suboptimal adherence where found to be 
independently associated with LTFU. Viral load was a strong predictor of LTFU with those with 
detectable viral load being 5 times likely to be LTFU. This is consistent with available studies 
looking at VL as a risk factor for LTFU on ART. Ndiaye, Ould-Kasi, Salleron and Bataile (2006) 
who conducted a case control study in France, found that a patient with a detectable viral load 
was almost 2 times more likely to be LTFU. The risk was higher with a VL>10 000 copies/ml. 
Our study did not analyze if different categories of viral loads had an effect on the risk to LTFU. 
A cohort study conducted in South Africa amongst patients above 14 years old, those with a 
detectable viral load had a 3 times higher risk of becoming LTFU (Mberi, Dube, Kuonza & 
Nattey, 2015). Our study shows that adolescents could be at a much higher risk of LTFU if they 
have a detectable VL, compared to the adult population. It is important to note that after a 
thorough search, there are few studies in this region which analyze the link between VL and 
LTFU. This could be due to the fact that most ART programs in sub-Saharan Africa do not use 
VL measurements for treatment monitoring amongst patients on ART, with only South Africa, 
Botswana, Namibia and Rwanda having VL available ( IAS, 2014).  
In this study patients with suboptimal adherence (<95%) were more than 3 times at risk of LTFU 
after multivariate analysis. This is consistent with a  case control study conducted in Ethiopia by 
Mergeso, Garoma, Eticha and Workineh (2016), who found that adult patients with adherence 
<95% were 7 times more likely to be LTFU. The association between suboptimal adherence and 
LTFU was also found in a retrospective observational study conducted in Nigeria (Meloni, 
Chaplain, Chang & Rawizza, 2015) and another one conducted in Kenya amongst pregnant 
women (Clayden, 2012). It seems this study amongst an adolescent population is consistent with 
adult studies on the association between suboptimal adherence and LTFU.  Adherence support is 
therefore critical in improving patient outcomes amongst all patients, including adolescents on 
ART.  
Low CD4 count (at LTFU) has been identified as a predictor of LTFU in most studies. Maskew, 
MacPhail, Menezes and Rubel (2007) and Makunde, Francis and Kamugisha (2012) found that 
adult patients who were LTFU had a low median CD4 count, of 92 and 122 cells/µL 
respectively. This is in contrast with this study, which had the majority (62%) of those LTFU 
with an absolute CD4 count ≥350 cells/µL.  This could be due the physiological difference of 
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CD4 count amongst children and adults. CD4 counts are generally higher amongst children when 
compared to adults (Denny, Yogev & Gelman, 1992). In this study the majority were 
commenced on ART in early childhood when CD4 counts are expected to be higher. 
Bivariate findings in this study were inconsistent with a study done in Ethiopia in which 
Dessalegn, Tsadik and Lemma (2014) found no association between low CD4 count and LTFU 
in their study done amongst adult clients. However, similarly, there was no relationship after 
multivariate analysis, hence the results seem similar.  
In this study there was no statistically significant independent associations between history of TB 
disease and LTFU after multivariate analysis (odds ratio=2.03 (0.93-4.41). This is despite an 
association in the bivariate analysis with 24% of those LTFU having a past history of TB 
compared to 14% in those not LTFU. In contrast a study done in Ethiopia by Tardesse and Haile 
(2014) showed statistically significant relationship between TB and LTFU in multivariate 
analysis.  The difference with our study is that we looked at past history of both presumed and 
confirmed TB cases, whilst the Ethiopian study used proven cases of TB, confirmed by 
microscopy and so may be more accurate.  Tayler-Smith, Zachariah, Manzi and Kizito (2011) 
and Alvarez-Uria, Naik, Pakam and Midde (2013) also showed increased risk of LTFU amongst 
HIV positive patients on ART who were diagnosed with TB. However, these studies examined 
the presence of TB at the time of LTFU, whilst our study used past history of TB disease.  
Increased risk of LTFU whilst on TB treatment could occur due to the increased pill burden and 
also side effects associated with concurrent ART and TB drugs. However this could not be 
investigated in my study.  
This study did not find any independent association between LTFU and WHO clinical staging, 
with the odds ratio being 1.29(0.75-2.21) after multivariate analysis. This contradicts most 
studies on LTFU. Mergeso, Garoma, Eticha and Workineh (2016) in a study conducted in 
Ethiopia found that the risk of LTFU was 2-fold if a patient had a stage IV condition compared 
to Stage 1 in multivariate analysis.  Also Saka, Landoh and Patassi (2013) in a Togolese study 
showed that patients with WHO stage III/IV were almost 2 times at risk of LTFU. A 
retrospective cohort study conducted in South Africa the risk of LTFU was also 2 times when 
WHO stage was III/IV compared to stage I/II (Mberi, Dube, Kuonza & Nattey, 2015). However, 
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Berherto, Haile and Mohammed (2014) found that higher WHO stages III/IV were associated 
with less risk of LTFU. All of these studies, which found associations between WHO stage and 
LTFU were adult studies. In our study the great majority of those LTFU and those not LTFU 
commenced ART in childhood. We found that the greatest proportion of those LTFU (74%) and 
those not LTFU (69%) both had advanced HIV disease (WHO stage III/IV), so differences in 
this association may be difficult to discern.  This is with agreement with evidence that most 
children start ART in advanced stages of HIV. A study conducted in Malawi, Swaziland and 
Lesotho found that 70% of pediatric HIV positive patients had WHO stage III/IV at ART 
initiation (Kabue, Buck, Wanless & Cox, 2012). 
In bivariate analysis there was an association between LTFU and the ART regimen.  Adolescents 
on LPV/r-based regimen were twice as likely to be LTFU compared to those on an NNRTI-
based regimen. Anecdotal evidence from the study site shows that adolescent patients complain 
of intolerance to LPV/r based regimens, in particular the size of the tablets, which could lead to 
defaulting medication, although this needs further study. However there was no independent 
significant association between LTFU and ART-regimen after multivariate analysis. No 
difference was found in LTFU with a parent or non-parent being the caregiver of the adolescent. 
This is in contrast to a study conducted in South Africa, which showed that the parent being the 
caregiver was associated with higher risk of LTFU (Sengayi, Dwane, Marinda, Sipambo, Farlie 
& Moultrie, 2012). However the South African study was amongst children less than 12 years 
old and may be related to a parent’s own health condition and could be explored further.  
The main limitation of this study is that the results cannot be extrapolated in other sites in 
Botswana, in particular public clinics that have a different set up and are solely public sector 
clinics. Hence this is most likely a ‘best case scenario’ situation. There may be some missed 
associations in public sector clinics. It is also important to conduct qualitative research such as 
focus group discussions and individual interviews at the site in order to determine psychosocial 
factors associated with LTFU so that counseling sessions can be focused on the particular factors 
which are identified as related to LTFU in bivariate analysis. In addition, it would be valuable to 
conduct quantitative studies in commoner public sector clinics. 
 
http://etd.uwc.ac.za/
  
 
 
35 
 
                              CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
This study found that adolescent patients on ART at Baylor Clinic who had suboptimal 
adherence and detectable viral load were at higher risk of LTFU. Unlike most available studies 
conducted in sub-Saharan Africa there was no association between LTFU and the CD4 count. 
However increasingly, detectable viral load is the best marker for use in clinical adherence. The 
findings in our study will assist clinicians at the study site to identify patients who need extra 
support to be retained in care and hence improve clinical outcomes. The findings highlight the 
importance of paying closer attention to particularly middle and late adolescents with adherence 
challenges in this setting, so that factors leading to poor adherence can be addressed. Similarly 
among adolescents with a detectable VL, measures such as more regular follow up and 
intensified adherence counseling sessions should be implemented so as to prevent LTFU.  
Appropriate adherence information should be provided to all adolescents on ART who are at risk 
of LTFU at every clinic visit i. e both consultation and pill refill visits. This requires a multi-
disciplinary team of doctors, nurses, pharmacists, counselors, peer educators and psychologists.  
Adolescent patients who were LTFU had a greater proportion on PI-based regimen (Aluvia), 
although this was not statistically significant in multivariate analysis. This needs to be further 
explored with a qualitative study as anecdotal evidence at the site shows that most adolescents 
complain of intolerance due to the larger size of the tablets. If this is explored and shown to be 
the case, then other treatment options which are better are tolerated need to be identified so as to 
improve adherence and retention in care of adolescents on ART.  
More studies of this type are needed in solely public sector clinics in Botswana and in this region 
of the world in where the epidemic is largest, as there is a sizeable population of patients living 
with HIV in middle and late adolescents in which LTFU appears to be greatest, identifying 
influencing factors and interventions are needed. My study findings can be used to guide these 
studies and help uncover further factors influencing LTFU in middle and late adolescents on 
ART. 
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APPENDIX 1 
Data collection tool  (For operational definitions of variables, see appendix 1a) 
 
Record 
No. 
LFTU
(1) or 
non-
LTFU
(0) 
Age  Sex Baseline 
CD4 
CD4 
prior to 
LTFU 
Viral 
Load 
prior to 
LFTU 
WHO 
Stage 
ART 
Regimen 
Prior 
TB/HIV  
Primary 
Care 
Giver 
Adherence 
>95%(Yes/No 
1            
2            
3            
4            
5            
6            
7            
8            
9            
10            
11            
12            
13            
14            
15            
16            
17            
18            
19            
20            
21            
22            
23            
24            
25            
26            
27            
28            
29            
30            
31            
etc            
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Appendix 1a –Operational definitions of variables 
Age- recorded as a continuous variable. 
Gender- Male or Female 
Baseline CD4-   CD4 <350 or CD4≥ 350 
CD4 at lost to follow- CD4<350 or CD4≥350 
Viral load (at lost to follow) – Non-Detectable, VL <1000copies/ml in prior 6 months 
- Detectable, at least one VL>1000 in the prior 6 months. 
WHO staging    - mild stage (stage 1 or 2) 
                           -Advanced stage (stage 3 or 4) 
ART regimen – NNRTI-based regimens or Protease Inhibitor (PI) based regimen. 
TB/HIV co-infection- Yes or No 
Adherence by pill counts- Poor (adherence <95% in the prior year) 
- Good ( adherence ≥95% in the prior year) 
Relationship to primary caregiver-    Biological Parents 
-         Other 
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